Antibody responses to NY-ESO-1 in primary breast cancer identify a subtype target for immunotherapy

PLoS ONE

Volumn 6, Issue 6, 2011, Pages

  Hamaï, Ahmed ^a   Duperrier Amouriaux, Karine ^a   Pignon, Pascale ^a   Raimbaud, Isabelle ^a   Memeo, Lorenzo ^b   Colarossi, Cristina ^b   Canzonieri, Vincenzo ^c   Perin, Tiziana ^c   Classe, Jean Marc ^d   Campone, Mario ^a,d   Jézéquel, Pascal ^d   Campion, Loïc ^d   Ayyoub, Maha ^a   Valmori, Danila ^a,e  

^a INSERM   (France)

^b Mediterranean Institute of Oncology   (Italy)

^c CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^d CLCC René Gauducheau ^*  (France)

^e UNIVERSITÉ DE NANTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CYTOKERATIN 14; CYTOKERATIN 5; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; IMMUNOGLOBULIN G ANTIBODY; NY ESO 1 ANTIBODY; NY ESO 1 ANTIGEN; PROGESTERONE RECEPTOR; PROTEIN P63; UNCLASSIFIED DRUG; CANCER ANTIBODY; CTAG1B PROTEIN, HUMAN; MEMBRANE PROTEIN; TUMOR ANTIGEN;

ADULT; AGED; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIBODY TITER; ANTIGEN EXPRESSION; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER INFILTRATION; CANCER INVASION; COHORT ANALYSIS; CONTROLLED STUDY; FAMILY HISTORY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRADUCTAL CARCINOMA; INVASIVE CARCINOMA; LYMPH NODE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PRIMARY TUMOR; PROTEIN EXPRESSION; TUMOR IMMUNITY; TUMOR VOLUME; BREAST TUMOR; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; METHODOLOGY; PATIENT SELECTION; TUMOR CELL LINE;

ANTIBODIES, NEOPLASM; ANTIBODY SPECIFICITY; ANTIGENS, NEOPLASM; BREAST NEOPLASMS; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOTHERAPY; MEMBRANE PROTEINS; PATIENT SELECTION; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 79959254308     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0021129     Document Type: Article

References (21)

1. Smith IE, Dowsett M, (2003) Aromatase inhibitors in breast cancer. N Engl J Med 348: 2431-2442.
2. Burstein HJ, (2005) The distinctive nature of HER2-positive breast cancers. N Engl J Med 353: 1652-1654.
3. Hortobagyi GN, (2005) Trastuzumab in the treatment of breast cancer. N Engl J Med 353: 1734-1736.
4. Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ, (2005) Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer 5: 615-625.
5. Ross MT, Grafham DV, Coffey AJ, Scherer S, McLay K, et al. (2005) The DNA sequence of the human X chromosome. Nature 434: 325-337.
6. Jäger E, Chen YT, Drijfhout JW, Karbach J, Ringhoffer M, et al. (1998) Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med 187: 265-270.
7. Valmori D, Dutoit V, Liénard D, Rimoldi D, Pittet M, et al. (2000) Naturally occurring HLA-A2 restricted CD8+ T cell response to the cancer testis antigen NY-ESO-1 in melanoma patients. Cancer Res 60: 4499-4506.
8. Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, et al. (2009) The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 15: 5323-5337.
9. Valmori D, Souleimanian NE, Tosello V, Bhardwaj N, Adams S, et al. (2007) Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming. Proc Natl Acad Sci U S A 104: 8947-8952.
10. Hunder NN, Wallen H, Cao J, Hendricks DW, Reilly JZ, et al. (2008) Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med 358: 2698-2703.
11. Valmori D, Souleimanian NE, Hesdorffer CS, Ritter G, Old LJ, et al. (2005) Identification of B cell epitopes recognized by antibodies specific for the tumor antigen NY-ESO-1 in cancer patients with spontaneous immune responses. Clin Immunol 117: 24-30.
12. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, et al. (2006) A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10: 515-527.
13. Odunsi K, Jungbluth AA, Stockert E, Qian F, Gnjatic S, et al. (2003) NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer. Cancer Res 63: 6076-6083.
14. Jungbluth AA, Chen YT, Stockert E, Busam KJ, Kolb D, et al. (2001) Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues. Int J Cancer 92: 856-860.
15. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, et al. (2000) Molecular portraits of human breast tumours. Nature 406: 747-752.
16. Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, et al. (2005) Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 11: 5678-5685.
17. Sotiriou C, Pusztai L, (2009) Gene-expression signatures in breast cancer. N Engl J Med 360: 790-800.
18. Pageau GJ, Hall LL, Ganesan S, Livingston DM, Lawrence JB, (2007) The disappearing Barr body in breast and ovarian cancers. Nat Rev Cancer 7: 628-633.
19. Jager E, Stockert E, Zidianakis Z, Chen YT, Karbach J, et al. (1999) Humoral immune responses of cancer patients against "Cancer-Testis" antigen NY-ESO-1: correlation with clinical events. Int J Cancer 84: 506-510.
20. Stockert E, Jager E, Chen YT, Scanlan MJ, Gout I, et al. (1998) A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med 187: 1349-1354.
21. Ayyoub M, Deknuydt F, Raimbaud I, Dousset C, Leveque L, et al. (2009) Human memory FOXP3+ Tregs secrete IL-17 ex vivo and constitutively express the T(H)17 lineage-specific transcription factor RORgamma t. Proc Natl Acad Sci U S A 106: 8635-8640.